Meta Sued For Using Medical Data Without Permission

August 4, 2022

A new lawsuit is accusing Meta of using the medical data of people without permission.

The lawsuit alleges that Meta has unauthorized access to the private medical data of millions of people and that the company uses the data to conduct targeted medicine and treatment advertising on Facebook.

The lawsuit, filed last week in the Northern District of California, accuses U.S. hospitals of providing Meta with sensitive patient data and violating HIPAA.

The complaint accused some hospitals of using Meta’s Pixel, a tool that allows companies to measure and build audiences for ad campaigns to access patients’ password-protected portals and share sensitive health information that Meta then sold to Facebook advertisers.

The lawsuit accuses Meta of knowingly collecting sensitive medical information from health websites, even though the company’s policies prohibit advertisers from disclosing data that includes health, financial or other categories of sensitive information.

To substantiate the claims made, the complaint shares the experience of a Facebook user who began receiving targeted ads for heart and knee-related drugs that were posted on her private patient portal at the University of California, San Francisco Medical Center.

The sources for this piece include an article in BusinessInsider.

Top Stories

Related Articles

February 11, 2026 Workday’s CEO Carl Eschenbach is stepping down, less than a week after the enterprise software firm announced more...

February 11, 2026 OpenAI is losing several senior-level researchers and executives as it redirects resources toward its flagship ChatGPT product, more...

February 10, 2026 Canada is about to make history in the race for clean energy by taking a homegrown fusion more...

February 9, 2026 Waymo acknowledged recently that human workers, including contractors operating from overseas, still play a direct role in more...

Jim Love

Jim is an author and podcast host with over 40 years in technology.

Share:
Facebook
Twitter
LinkedIn